Prospective, Observational, Multicentre, Single Group, Open-label Study to Confirm the Safety and Effectiveness of BIOCHROMADERM® Ink for the Reconstruction of the Nipple-areola Complex in Patients Undergoing Breast Reconstructive Surgery Following Mastectomy

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

The goal of this observational study is to: * To confirm the continued performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 3 months post-pigmentation; * To confirm the continued safety of BIOCHROMADERM®, * To confirm adequate usability and describe the optimal process for BIOCHROMADERM® implantation * To assess the long-term performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 12 months post-pigmentation (Likert scale) * To assess the evolution of performance (Likert scale) between baseline, 3 months and 12 months post-pigmentation * To assess fading (pigment retention potential) over 12 months * To assess the number of pigmentation adjustments needed per patient throughout the study duration * To assess patient's satisfaction/self-confidence evolution post-treatment, both in terms of general breast appearance and as to the specific dermo-pigmentation stage * To assess the correlation of the esthetic satisfaction/self-confidence questionnaire outcomes with those of the Likert Scale and patient satisfaction VAS at 3 months and 12 months post-pigmentation

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Female or male ≥18 years old,

• Requiring the reconstruction of the nipple-areola complex following mastectomy,

• Affiliated or beneficiary of a social security scheme,

• Able and willing to provide written informed consent to study participation.

Locations
Other Locations
France
Centre Oscar Lambret
NOT_YET_RECRUITING
Lille
Hôpital de La Conception
RECRUITING
Marseille
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITING
Vandœuvre-lès-nancy
Contact Information
Primary
Marie-Hélène BACHELEY
regulatory@biotic.fr
+33785453676
Time Frame
Start Date: 2025-11-12
Estimated Completion Date: 2027-06-12
Participants
Target number of participants: 115
Related Therapeutic Areas
Sponsors
Leads: Laboratoires BIOTIC Phocea
Collaborators: Clinical Research Consultants, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials